These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 37374329)

  • 1. Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept.
    Ohara H; Harada Y; Hiyama T; Sadahide A; Minamoto A; Kiuchi Y
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374329
    [No Abstract]   [Full Text] [Related]  

  • 2. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
    Sahni J; Patel SS; Dugel PU; Khanani AM; Jhaveri CD; Wykoff CC; Hershberger VS; Pauly-Evers M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Osborne A; Weikert R; Fauser S
    Ophthalmology; 2019 Aug; 126(8):1155-1170. PubMed ID: 30905643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
    Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
    Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Curran K; Lucenteforte E; Peto T; Parravano M
    Cochrane Database Syst Rev; 2023 Jun; 2023(6):CD007419. PubMed ID: 38275741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Effects of Switching to Faricimab in Eyes with Diabetic Macular Edema Refractory to Aflibercept.
    Tatsumi T; Kaiho T; Iwase T; Miura G; Shimizu D; Niizawa T; Ozawa Y; Arai M; Oshitari T; Takatsuna Y; Baba T
    Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792915
    [No Abstract]   [Full Text] [Related]  

  • 6. Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema.
    Pichi F; Abdi A; Aljneibi S; El Ghrably I; Agarwal A; Ghazi NG
    Int Ophthalmol; 2024 Jun; 44(1):275. PubMed ID: 38916818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis.
    Watkins C; Paulo T; Bührer C; Holekamp NM; Bagijn M
    Adv Ther; 2023 Dec; 40(12):5204-5221. PubMed ID: 37751021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema.
    Kusuhara S; Kishimoto-Kishi M; Matsumiya W; Miki A; Imai H; Nakamura M
    Medicina (Kaunas); 2023 Mar; 59(4):. PubMed ID: 37109622
    [No Abstract]   [Full Text] [Related]  

  • 9. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection.
    Nawar AE; Wasfy T; Shafik HM
    BMC Ophthalmol; 2022 Jun; 22(1):287. PubMed ID: 35768859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema.
    Khalil MMAA; Mansour HO; Tawfik AMR; Elmahdy AG
    BMC Ophthalmol; 2022 Dec; 22(1):492. PubMed ID: 36522705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.
    Ozkaya A; Demir G; Kirmaci A
    Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study.
    Isik P; Sizmaz S; Esen E; Uysal A; Demircan N
    Int Ophthalmol; 2023 Nov; 43(11):4171-4180. PubMed ID: 37505290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
    Liberski S; Wichrowska M; Kocięcki J
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal Ranibizumab Versus Aflibercept for Diabetic Macular Edema in Vitrectomized Eyes: 12 Month Results.
    Türkseven Kumral E; Erçalık NY
    Semin Ophthalmol; 2021 Nov; 36(8):723-727. PubMed ID: 33760698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice.
    Plaza-Ramos P; Borque E; García-Layana A
    PLoS One; 2019; 14(10):e0223793. PubMed ID: 31644594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment.
    Hong IH; Choi W; Han JR
    Jpn J Ophthalmol; 2020 Mar; 64(2):196-202. PubMed ID: 31900869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment.
    Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F
    Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.